Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2022-06-10 Major Shareholding Noti…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages held by JPMorgan Chase & Co. (crossing thresholds) and provides specific breakdowns of direct and indirect holdings, including instruments. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns with the Major Shareholding Notification category (MRQ). Although it is a regulatory filing disseminated via DGAP, the specific content points strongly to MRQ over the general RNS fallback.
2022-06-10 English
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
Regulatory Filings Classification · 1% confidence The document is a press release dated June 10, 2022, announcing that MorphoSys AG is presenting multiple analyses from the MANIFEST Phase 2 clinical trial regarding their drug Pelabresib at the European Hematology Association (EHA) 2022 Congress. It details clinical findings, mentions future trial designs (MANIFEST-2), and includes standard corporate boilerplate and contact information. This is a general corporate announcement about scientific data presentation, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a news announcement about corporate/scientific activity that doesn't fit the highly specific categories (like DIV, CAP, MANG), it falls best under the general Regulatory Filings/News category, which is RNS, or potentially an Investor Presentation (IP) if it were the presentation itself, but this is the *announcement* of the presentation. Given the context of DGAP distribution and the nature of the content (scientific data release announcement), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly resembles an Investor Presentation announcement. However, since it is primarily a news release about data being presented at a conference, RNS is the best fit among the provided options for a general corporate/scientific update announcement.
2022-06-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' by JPMorgan Chase & Co. in MorphoSys AG, referencing specific German securities law (WpHG) articles (Article 40, Section 1). This type of filing reports changes in significant share ownership thresholds. This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a formal notification of a change in voting rights percentage crossing a threshold, which is the core function of an MRQ filing.
2022-06-08 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections detailing the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG). It reports changes in the percentage of voting rights held by JPMorgan Chase & Co. (crossing thresholds) on May 30, 2022. This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category.
2022-06-03 English
MorphoSys AG Reports Outcome of Annual General Meeting 2022
AGM Information Classification · 1% confidence The document is titled "MorphoSys AG Reports Outcome of Annual General Meeting 2022" and explicitly states that shareholders approved all proposed resolutions at the virtual Annual General Meeting (AGM) held on May 18, 2022. This content directly relates to the results and proceedings of the AGM. According to the definitions, materials shared during the Annual General Meeting fall under the 'AGM Information' category (Code: AGM-R). Although it reports the outcome, it is fundamentally an announcement about the AGM proceedings, making AGM-R the most precise fit over DVA (which is strictly for voting results) or RPA (which is for announcing the publication of a report, not the meeting outcome itself).
2022-05-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages held by a legal entity (The Goldman Sachs Group, Inc.) in MorphoSys AG, crossing specific thresholds (0.23% direct, 7.21% instruments). This type of mandatory disclosure regarding changes in significant share ownership directly corresponds to the definition of Major Shareholding Notification.
2022-05-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.